Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 6
Submit an article Journal homepage
61
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Toxicity profiles of HER2/neu peptide anticancer vaccines: the picture from Phase/I and II clinical trials

Constantin N Baxevanis Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece. [email protected]
,
Michael Papamichail Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece. [email protected]
&
Sonia A Perez Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece. [email protected]
Pages 637-640 | Published online: 09 Jan 2014

References

  • Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl. 2), 1–13 (2001).
  • Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5(7), 953–962 (1990).
  • Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER2/neu as a target for cancer vaccines. Immunotherapy 2(2), 213–226 (2010).
  • Perez SA, von Hofe E, Kallinteris NL et al. A new era in anticancer peptide vaccines. Cancer 116(9), 2071–2080 (2010).
  • Peoples GE, Gurney JM, Hueman MT et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 23(30), 7536–7545 (2005).
  • Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol. Rev. 222, 316–327 (2008).
  • Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14(3), 797–803 (2008).
  • Benavides LC, Gates JD, Carmichael MG et al. The impact of HER2/neu expression level on response to the E75 vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 15(8), 2895–2904 (2009).
  • Hueman MT, Dehqanzada ZA, Novak TE et al. Phase/I clinical trial of a HER2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin. Cancer Res. 11(20), 7470–7479 (2005).
  • Gates JD, Carmichael MG, Benavides LC et al. Long-term follow-up assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J. Am. Coll. Surg. 208(2), 193–201 (2009).
  • Carmichael MG, Benavides LC, Holmes JP et al. Results of the first Phase 1 clinical trial of the HER2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 116(2), 292–301 (2010).
  • Holmes JP, Benavides LC, Gates JD et al. Results of the first Phase/I clinical trial of the novel II-key hybrid preventive HER2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26(20), 3426–3433 (2008).
  • Sears AK, Perez SA, Clifton GT et al. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin. Biol. Ther. 11(11), 1543–1550 (2011).
  • Hale D, Perez S, Sears A et al. An update of a Phase II trial of the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Presented at: San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, USA, 6–10 December 2011.
  • Perez SA, Kallinteris NL, Bisias S et al. Results from a Phase/I clinical study of the novel Ii-Key/HER2/neu (776–790) hybrid peptide vaccine in patients with prostate cancer. Clin. Cancer Res. 16(13), 3495–3506 (2010).
  • Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27(28), 4685–4692 (2009).
  • Mittendorf E, Perez S, Tzonis P et al. Combination immunotherapy for breast cancer patients: safety and immunologic data from a Phase II trial administering a HER2/neu-derived peptide vaccine (AE37+GM-CSF) sequentially or concurrently with trastuzumab in the adjuvant setting. Presented at: San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, USA, 8–12 December 2010.
  • Vreeland T, Clifton G, Sears A et al. Long-term clinical benefit of adjuvant breast cancer vaccine: 5 year efficacy of E75 with multiple booster inoculations. Presented at: San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, USA, 6–10 December 2011.
  • Fleming KA, McMichael A, Morton JA, Woods J, McGee JO. Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer. J. Clin. Pathol. 34(7), 779–784 (1981).
  • Nehlin J, Isa A, Barington T. Immunogenicity and Immune-Modulating Properties of Human Stem Cells, Stem Cells in Clinic and Research. Gholamrezanezhad A (Ed.). InTech, Rijeka, Croatia (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.